I’m officially starting my faculty career in academic oncology as an Associate Professor @queensoncology@QueensUHealth from June 1st, 2021. I’m super excited about it, and very thankful to everyone who has had a role in making this happen. This is a twitter thread of gratitude.
First of all, I’m extremely thankful to my mentor Chris Booth. Honestly, Chris is the reason I moved to Queen’s. He has not only supported me in my career but has also been a great friend and advisor. I feel lucky to be working with him.
My immense gratitude to my mentor and department head @scottrberry. Scott has been incredibly supportive and helpful, and left no stones unturned to make this happen. He was never busy to not have time to listen to me. He’s a boss you’d want to work hard for.
I’m also incredibly lucky to have been hired at a time when our Dean is @janephilpott - a champion of global health and equity, and an inspiration icon to us all @QueensUHealth. Thank you for your trust in me and support of global oncology work.
Also very thankful to Dr Bradley Stoner, the Department Head @QueensuPHS for the support, cross-appointment and for allowing me to teach a super cool course (details to follow in the future).
Thankful to all my past mentors in Nepal, Japan and USA for their guidance and mentorship, and to my current colleagues and mentors for helping me personally and professionally settle in Queen’s/Kingston.
Specially grateful to @EAEisenhauer who is my role model in oncology and in personal life. One day, if some mentee feels about me the way I feel about her, that’d be my definition of success. She is also the first person to send me these flowers. 😊 Thank you for everything.
Finally, I’m extremely grateful to @oicr_news for the support of my work. This has meant a lot, and I feel so much more motivated to continue to do the cancer policy work that benefits patients in Ontario, Canada and globally.
Thank you all my patients who have been the best teachers. Thank you family for bearing with my abnormal work pattern and absence from home. Thank you collaborators, I have learned so much working with you all. Thank you friends -including tweeps-for always being there for me.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
It was my pleasure sharing some thoughts on communication skills in oncology with the participants of @ecancer#Kolkata21 meeting today morning. The video is already available to watch for those interested: ecancer.org/en/video/9670-…
With special thanks to @ChernyNathan@scottrberry and @ramsedhom for providing me advice/thoughts/slides to make this talk possible. I myself learned a lot in this process.
Many thanks to @HealthCommunic2 for organizing the event. Missed meeting all dear friends and colleagues in person, hopefully next year we can.
For the first time, we now have official data on the commonest cancers in Kathmandu by incidence and mortality in different subgroups of population. ascopubs.org/doi/full/10.12…
The population-based cancer registry has only just started in Nepal, and there are plenty of room for improvement. But I hope this provides the foundation for stronger work in the future. ascopubs.org/doi/full/10.12…
Very happy to see this announcement today from @FDAOncology . Early approval based on surrogate and appropriate action upon failure to confirm clinical benefit in confirmatory trial is the mandate of accelerated approval. fda.gov/news-events/fd…
Several of our works @PORTAL_Research have previously highlighted that this follow-through has not been happening. Failure to act when drugs fail to improve clinical benefit in confirmatory trials breaks the social compromise of AA. I will share 2 imp papers in this regard.
First, in this @JAMAInternalMed paper we published last year, we show that confirmatory trials do not confirm clinical benefit using survival endpoints and even when confirmatory trials fail, no actions are usually taken. jamanetwork.com/journals/jamai…@akesselheim
This thread is going to be a collection of all my #globaloncology papers, primarily for my own reference to bookmark for quick access but also, just in case, it is helpful for any colleague with an interest in global oncology. 1/
This is probably one of the most important papers we’ve ever published. This paper in British Journal of Hematology highlights the story of how Bone Marrow Transplant services started in Nepal under @Poudyalbishesh ‘s initiative. onlinelibrary.wiley.com/doi/full/10.11…
Seems like this is the time to look back upon your year. Here’s a thread on my tweets from 2019 that I’d like to share again with the new followers. No particular order. Here’s the first one: medscape.com/viewarticle/91… I learned a lot by reading all the comments to this piece.
There's a great coverage today in @Medscape of our latest @bmj_latest paper. Unfortunately, I'll have to disagree with these comments from an expert which I find disrespectful. RANTORIAL ahead. medscape.com/viewarticle/90…
All 4 authors in our @bmj_latest paper are medical oncologists. It's our daily job to talk to patients about benefits and side effects of cancer drugs. What's the basis for suggesting that we didn't talk to patients? The no. of medical oncologists in the world is ..surprise. >1!
This statement assumes that cancer drugs make a difference between living and dying. I wish that were true, but it's not. This is false dichotomy. It's nearly always a trade-off, not such a clear dichotomy: life with drug, death without drug. Such false dichotomies hurt pts.